Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review
Open Access
- 20 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 12 (1), 30
- https://doi.org/10.1186/1471-2407-12-30
Abstract
The role of human papillomavirus (HPV) in malignant and non-malignant genital diseases in women is well known and the corresponding epidemiological burden has been widely described. However, less is known about the role of HPV in anal, penile and head and neck cancer, and the burden of malignant and non-malignant HPV-related diseases in men. The objective of this review is to estimate the epidemiological burden of HPV-related cancers and non-malignant diseases in men in Europe. The annual number of new HPV-related cancers in men in Europe was estimated using Eurostat population data and applying cancer incidence rates published by the International Agency for Research on Cancer. The number of cancer cases attributable to HPV, and specifically to HPV16/18, was calculated based on the most relevant prevalence estimates. The annual number of new cases of genital warts was calculated from the most robust European studies; and latest HPV6/11 prevalence estimates were then applied. A literature review was also performed to retrieve exhaustive data on HPV infection at all anatomical sites under study, as well as incidence and prevalence of external genital warts, recurrent respiratory papillomatosis and HPV-related cancer trends in men in Europe. A total of 72, 694 new cancer cases at HPV-related anatomical sites were estimated to occur each year in men in Europe. 17,403 of these cancer cases could be attributable to HPV, with 15,497 of them specifically attributable to HPV16/18. In addition, between 286,682 and 325,722 new cases of genital warts attributable to HPV6/11were estimated to occur annually in men in Europe. The overall estimated epidemiological burden of HPV-related cancers and non-malignant diseases is high in men in Europe. Approximately 30% of all new cancer cases attributable to HPV16/18 that occur yearly in Europe were estimated to occur in men. As in women, the vast majority of HPV-positive cancer in men is related to HPV16/18, while almost all HPV-related non-malignant diseases are due to HPV6/11. A substantial number of these malignant and non-malignant diseases may potentially be prevented by quadrivalent HPV vaccination.Keywords
This publication has 91 references indexed in Scilit:
- Genital warts and cost of care in EnglandSexually Transmitted Infections, 2011
- Worldwide burden of cervical cancer in 2008Annals Of Oncology, 2011
- Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort studyThe Lancet, 2011
- Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance dataThe Lancet Infectious Diseases, 2011
- The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy MenCancer Epidemiology, Biomarkers & Prevention, 2011
- Incidence trends and survival of penile squamous cell carcinoma in the NetherlandsInternational Journal of Cancer, 2010
- Human papillomavirus prevalence and type distribution in penile carcinomaJournal of Clinical Pathology, 2009
- The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United StatesCancer Epidemiology, Biomarkers & Prevention, 2008
- Penile, Urethral, and Seminal Sampling for Diagnosis of Human Papillomavirus Infection in MenJournal of Clinical Microbiology, 2007
- Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002British Journal of Cancer, 2006